Literature DB >> 20524095

A second national questionnaire survey of TMA.

Naomi Ito-Habe1, Hideo Wada, Masanori Matsumoto, Yoshihiro Fujimura, Mitsuru Murata, Takashi Izuno, Minoru Sugita, Yasuo Ikeda.   

Abstract

A second questionnaire survey of Japanese patients with thrombotic microangiopathy (TMA) was carried out to investigate the frequency, laboratory abnormalities and outcome in 2004 and 2005. The first and second surveys evaluated 397 patients including 19 with familial TMA and 378 with acquired TMA. The patients with acquired TMA included 165 with Escherichia coli O-157 infection-related TMA (O-157 TMA), 70 with ADAMTS13-related TMA (ADAMTS13 TMA) and 38 with other types of TMA (other TMA). The rate of ADAMTS13 TMA was significantly higher in patients with collagen diseases than in patients with all other underlying diseases (p < 0.001). The treatment of acquired TMA included plasma exchange (PE), steroids, antiplatelet agents, and anticoagulants, PE was carried out in 91.4% of patients with ADAMTS13 TMA, 68.4% of patients with other TMA and 12.7% of patients with O-157 TMA. The efficacy of PE and steroid therapy tended to be higher in patients with ADAMTS13 TMA than in those with other TMA. The complete remission rate was the highest and the mortality rate was the lowest in the patients with O-157 TMA. The mortality rate tended to be lower in patients with ADAMTS13 TMA than in those with other TMA. However, not all of the patients in our study were examined for ADAMTS13 at the time that this questionnaire survey was conducted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524095     DOI: 10.1007/s12185-010-0599-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

1.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

Review 2.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

3.  Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.

Authors:  Seiji Kato; Masanori Matsumoto; Tomomi Matsuyama; Ayami Isonishi; Hisahide Hiura; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2006-08       Impact factor: 3.157

4.  Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.

Authors:  Y Asada; A Sumiyoshi; T Hayashi; J Suzumiya; K Kaketani
Journal:  Thromb Res       Date:  1985-06-01       Impact factor: 3.944

5.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.

Authors:  T W Chow; N A Turner; M Chintagumpala; P D McPherson; L H Nolasco; L Rice; J D Hellums; J L Moake
Journal:  Am J Hematol       Date:  1998-04       Impact factor: 10.047

Review 7.  Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.

Authors:  Eric Chun-Yet Lian
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 8.  The management of thrombotic thrombocytopenic purpura in 2005.

Authors:  Gail Rock
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

9.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

10.  The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Masanori Matsumoto; Hideo Yagi; Hiromichi Ishizashi; Hideo Wada; Yoshihiro Fujimura
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

View more
  3 in total

1.  Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.

Authors:  Moon Ju Jang; So Young Chong; In-Ho Kim; Jee-Hyun Kim; Chul-Won Jung; Ja Young Kim; Ji-Chan Park; Sun Min Lee; Yeo-Kyeoung Kim; Ji-Eun Lee; Sung-Su Jang; Jin-Seok Kim; Deog-Yeon Jo; Dae-Young Zang; Young-Yiul Lee; Ho-Young Yhim; Doyeun Oh
Journal:  Int J Hematol       Date:  2011-02-03       Impact factor: 2.490

2.  Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.

Authors:  Takeshi Matsumoto; Xinping Fan; Eiji Ishikawa; Masaaki Ito; Keishirou Amano; Hidemi Toyoda; Yoshihiro Komada; Kohshi Ohishi; Naoyuki Katayama; Yoko Yoshida; Masanori Matsumoto; Yoshihiro Fujimura; Makoto Ikejiri; Hideo Wada; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2014-08-19       Impact factor: 2.490

3.  Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.

Authors:  Naomi Ito-Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Hidemi Toyoda; Eiji Ishikawa; Shinsuke Nomura; Yoshihiro Komada; Masaaki Ito; Tsutomu Nobori; Naoyuki Katayama
Journal:  Int J Hematol       Date:  2010-12-09       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.